Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis

NCT03443024 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03443024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03443024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
January 30, 2018
Completion date
May 23, 2019
Enrollment
280 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis